Revenue Soars for Adaptimmune, but Profitability Remains Elusive Adaptimmune Therapeutics reported a 195% jump in revenue in 2024, reaching $178 million. However, losses remain significant, and analysts predict sales may decline this year. The company’s lead asset, Tecelra, is driving growth, but concerns about cash burn and long-term sustainability persist.53